Moxisylyte
![]() | |
Systematic (IUPAC) name | |
---|---|
4-[2-(Dimethylamino)ethoxy]-5-isopropyl-2-methylphenyl acetate | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number |
54-32-0 ![]() |
ATC code | G04BE06 (WHO) C04AX10 |
PubChem | CID 4260 |
ChemSpider | 4110 |
UNII |
PW8QYA7KI0 ![]() |
KEGG |
D08239 ![]() |
Chemical data | |
Formula | C16H25NO3 |
Molar mass | 279.375 g/mol |
| |
| |
(verify) |
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction.[1] It is an α1-adrenergic antagonist.[2]
References
- ↑ British National Formulary 69, Chapter2.6.4, page 142
- ↑ Sakakibara R, Hattori T, Uchiyama T, et al. (March 2000). "Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte". J. Auton. Nerv. Syst. 79 (2–3): 191–5. doi:10.1016/S0165-1838(99)00105-8. PMID 10699651.
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.